TES7 and antibodies that bind thereto

1. A method of inhibiting the growth of a cancer cell that expresses the 4Ig form of B7H3, in an individual, said method comprising administering to said individual an effective amount of a composition comprising a substantially purified immunoglobulin polypeptide, or an antigen-binding fragment thereof, that specifically binds to said 4Ig form of B7H3 expressed on said cancer cell, but does not specifically bind to 2Ig B7H3 and is unable to cross-link 4Ig-B7H3.

2. The method of claim 1 , wherein said immunoglobulin polypeptide is an antibody or an antigen-binding fragment thereof.

3. The method of claim 1 , wherein said immunoglobulin polypeptide or antigen-binding fragment thereof is associated with a chemotherapeutic agent.

4. The method of claim 2 , wherein said antibody or antigen-binding fragment thereof is associated with a chemotherapeutic agent.

5. The method of claim 3 , wherein said cancer cell is a cancer cell selected from the group consisting of a cancer cell from an adrenal gland tumor, an AIDS-associated cancer, an alveolar soft part sarcoma, an astrocytic tumor, a bladder cancer, a bone cancer, a brain and spinal cord cancer, a metastatic brain tumor, a breast cancer, a carotid body tumor, a cervical cancer, a chondrosarcoma, a chordoma, a chromophobe renal cell carcinoma, a clear cell carcinoma, a colon cancer, a colorectal cancer, a cutaneous benign fibrous histiocytoma, a desmoplastic small round cell tumor, an ependymoma, a Ewing's tumor, an extraskeletal myxoid chondrosarcoma, a fibrogenesis imperfecta ossium, a fibrous dysplasia of the bone, a gallbladder and bile duct cancer, a gestational trophoblastic disease, a germ cell tumor, a head and neck cancer, an islet cell tumor, a Kaposi's Sarcoma, a kidney cancer, a leukemia, a lipoma/benign lipomatous tumor, a liposarcoma/malignant lipomatous tumor, a liver cancer, a lymphoma, a lung cancer, a medulloblastoma, a melanoma, a meningioma, a multiple endocrine neoplasia, a multiple myeloma, a myelodysplastic syndrome, a neuroblastoma, a neuroendocrine tumor, an ovarian cancer, a pancreatic cancer, a papillary thyroid carcinoma, a parathyroid tumor, a pediatric cancer, a peripheral nerve sheath tumor, a phaeochromocytoma, a pituitary tumor, a prostate cancer, a posterious uveal melanoma, a rare hematologic disorder, a renal metastatic cancer, a rhabdoid tumor, a rhabdomysarcoma, a sarcoma, a skin cancer, a soft-tissue sarcoma, a squamous cell cancer, a stomach cancer, a synovial sarcoma, a testicular cancer, a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer.

6. The method of claim 4 , wherein said cancer cell is a cancer cell selected from the group consisting of a cancer cell from an adrenal gland tumor, an AIDS-associated cancer, an alveolar soft part sarcoma, an astrocytic tumor, a bladder cancer, a bone cancer, a brain and spinal cord cancer, a metastatic brain tumor, a breast cancer, a carotid body tumor, a cervical cancer, a chondrosarcoma, a chordoma, a chromophobe renal cell carcinoma, a clear cell carcinoma, a colon cancer, a colorectal cancer, a cutaneous benign fibrous histiocytoma, a desmoplastic small round cell tumor, an ependymoma, a Ewing's tumor, an extraskeletal myxoid chondrosarcoma, a fibrogenesis imperfecta ossium, a fibrous dysplasia of the bone, a gallbladder and bile duct cancer, a gestational trophoblastic disease, a germ cell tumor, a head and neck cancer, an islet cell tumor, a Kaposi's Sarcoma, a kidney cancer, a leukemia, a lipoma/benign lipomatous tumor, a liposarcoma/malignant lipomatous tumor, a liver cancer, a lymphoma, a lung cancer, a medulloblastoma, a melanoma, a meningioma, a multiple endocrine neoplasia, a multiple myeloma, a myelodysplastic syndrome, a neuroblastoma, a neuroendocrine tumor, an ovarian cancer, a pancreatic cancer, a papillary thyroid carcinoma, a parathyroid tumor, a pediatric cancer, a peripheral nerve sheath tumor, a phaeochromocytoma, a pituitary tumor, a prostate cancer, a posterious uveal melanoma, a rare hematologic disorder, a renal metastatic cancer, a rhabdoid tumor, a rhabdomysarcoma, a sarcoma, a skin cancer, a soft-tissue sarcoma, a squamous cell cancer, a stomach cancer, a synovial sarcoma, a testicular cancer, a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer.

7. The method of claim 3 , wherein said chemotherapeutic agent is delivered into said cancer cell.

8. The method of claim 4 , wherein said chemotherapeutic agent is delivered into said cancer cell.

9. The method of claim 2 , wherein said antibody is a monoclonal antibody expressed by hybridoma ATCC No. PTA-7093 or a progeny thereof.

10. The method of claim 8 , wherein said antibody is a monoclonal antibody expressed by hybridoma ATCC No. PTA-7093 or a progeny thereof.

11. The method of claim 2 , wherein said antibody comprises a heavy chain variable region comprising the three heavy chain CDRs and a light chain variable region comprising the three light chain CDRs from the antibody produced by the host cell line having ATCC deposit number PTA-7093.

12. The method of claim 11 , wherein said antibody is a humanized antibody.

13. The method of claim 12 , wherein said heavy variable region of said humanized antibody comprises the amino acid sequence of SEQ ID NO:7 or SEQ ID NO: 8.

14. The method of claim 12 , wherein said light variable region of said humanized antibody comprises the amino acid sequence of SEQ ID NO:3 or SEQ ID NO: 4.

15. The method of claim 11 , wherein said antibody is a chimeric antibody comprising the heavy and light variable regions from the antibody produced by the host cell line having ATCC deposit number PTA-7093.

16. The method of claim 15 , wherein said chimeric antibody comprises a heavy chain constant region from the heavy chain constant region from a human antibody, and a light chain constant region from the light chain constant region of a human antibody.

17. The method of claim 11 , wherein said antigen-binding fragment is selected from the group consisting of a Fab, a Fab', a F(ab′) 2 and a Fv.

18. The method of claim 2 , wherein said antibody is a monoclonal antibody expressed by hybridoma A TCC No. PTA-8576 or a progeny thereof.

19. The method of claim 8 , wherein said antibody is a monoclonal antibody expressed by hybridoma A TCC No. PTA-8576 or a progeny thereof.

20. The method of claim 2 , wherein said antibody comprises a heavy chain variable region comprising the three heavy chain CDRs and a light chain variable region comprising the three light chain CDRs from the antibody produced by the host cell line having ATCC deposit number PTA-8576.

21. The method of claim 20 , wherein said antibody is a humanized antibody.

22. The method of claim 20 , wherein said antibody is a chimeric antibody comprising the heavy and light variable regions from the antibody produced by the host cell line having ATCC deposit number PTA-8576.

23. The method of claim 22 , wherein said chimeric antibody comprises a heavy chain constant region from the heavy chain constant region from a human antibody, and a light chain constant region from the light chain constant region of a human antibody.

24. The method of claim 20 , wherein said antigen-binding fragment is selected from the group consisting of a Fab, a Fab', a F(ab′) 2 and a Fv.

25. The method of claim 1 , wherein said method further comprises the administration of an additional diagnostic or therapeutic moiety.

26. The method of claim 1 , wherein cancer in said individual has previously been treated by surgery, radiation or chemotherapy.